Article
Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2013
Dai Jie, Kong Yan, Si Lu, Chi Zhihong, Cui Chuanliang, Sheng Xinan, Mao Lili, Li Siming, Lian Bin, Yang Ruifeng, Liu Shujing, Xu Xiaowei, Guo Jun
Abstract excerpt
PURPOSE: Platelet-derived growth factor receptor α (PDGFRA) is a target for tyrosine kinase inhibitor (TKI)-based targeted therapy. Dysregulation of PDGFRA has been reported in many cancers. However, PDGFRA mutations in melanomas have not been well studied. We analyzed the genetic mutations of PDGFRA in Chinese patients with melanoma and determined the inhibitory potency of TKIs, such as imatinib and crenolanib,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.